trial · primary record
daraxonrasib
Pancreatic Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 500 |
| Primary completion | 2030-07-10 |
| Primary endpoint | Disease-Free Survival (DFS) per Investigator |
| Registry ID | NCT07252232 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:48.298Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07252232
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.